Eupraxia Pharmaceuticals is trading 5.02% down at $6.34, with no clear company-specific catalyst dated August 31 identified.
- The decline extends the move from $6.67 on August 28, 2026.
- The latest company updates were its August 11 financial results and August 13 RESOLVE trial data release.
- Broader markets are modestly lower, but not enough to clearly establish a market-wide cause.